Data / Drug companies / Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC: 96 products in the FDA NDC directory, labeler code 0006
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Merck Sharp & Dohme LLC (labeler code 0006) lists 96 products in the FDA National Drug Code Directory, covering 37 finished drugs by generic name. By type: 64 prescription drugs, 26 vaccines. Its main marketing category is new drug applications (NDA). The newest product started marketing on July 15, 2026.
The request: Watch Merck Sharp & Dohme LLC (FDA labeler code 0006): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0006
- Products in commercial distribution
- 96
- Packages
- 176
- Finished drugs by generic name
- 37
- Prescription products
- 64
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 8
- Flagged as original packager
- 38 of 38 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- April 21, 1971
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 55 | 57.3% |
| Biologics (BLA) | 36 | 37.5% |
| Drugs for further processing | 5 | 5.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 64 | 66.7% |
| Vaccines | 26 | 27.1% |
| Drugs for further processing | 5 | 5.2% |
| Plasma derivatives | 1 | 1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Letermovir | 6 | 1 |
| Raltegravir | 5 | 6 |
| Hepatitis b vaccine (recombinant) | 5 | 4 |
| Sitagliptin and metformin hydrochloride | 5 | 8 |
| Aprepitant | 5 | 7 |
| Suvorexant | 4 | 1 |
| Hepatitis a vaccine, inactivated | 4 | 1 |
| Ertugliflozin and metformin hydrochloride | 4 | 1 |
| Sotatercept-csrk | 4 | 1 |
| Sitagliptin | 3 | 8 |
| Vericiguat | 3 | 1 |
| Ertugliflozin and sitagliptin | 2 | 1 |
| Pembrolizumab and berahyaluronidase alfa-pmph | 2 | 1 |
| Sterile water | 2 | 6 |
| Caspofungin acetate | 2 | 7 |
| Sugammadex | 2 | 22 |
| Ertugliflozin | 2 | 1 |
| Imipenem and cilastatin sodium | 1 | 2 |
| Vorinostat | 1 | 1 |
| Measles, mumps, and rubella virus vaccine live | 1 | 1 |
| Doravirine | 1 | 2 |
| Elbasvir and grazoprevir | 1 | 1 |
| Imipenem anhydrous, cilastatin, and relebactam anhydrous | 1 | 1 |
| Ivermectin | 1 | 33 |
| Pembrolizumab | 1 | 1 |
| Belzutifan | 1 | 1 |
| Fosaprepitant dimeglumine | 1 | 12 |
| Ertapenem sodium | 1 | 11 |
| Measles, mumps, rubella and varicella virus vaccine live | 1 | 1 |
| Varicella virus vaccine live | 1 | 1 |
| Latrodectus mactans | 1 | 2 |
| Bezlotoxumab | 1 | 1 |
| Zaire ebolavirus (strain kikwit-95) envelope glycoprotein | 1 | 1 |
| Lipfendra | 1 | 1 |
| Doravirine, lamivudine, and tenofovir disoproxil fumarate | 1 | 1 |
| Clesrovimab | 1 | 1 |
| Doravirine, islatravir | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 34 | 35.4% |
| Injection, suspension | 15 | 15.6% |
| Injection, solution | 13 | 13.5% |
| Kit | 6 | 6.2% |
| Capsule | 4 | 4.2% |
| Injection, powder, lyophilized, for solution | 4 | 4.2% |
| Injection, powder, for solution | 3 | 3.1% |
| Injection, powder, lyophilized, for suspension | 3 | 3.1% |
| Tablet, film coated, extended release | 3 | 3.1% |
| Injection | 2 | 2.1% |
| Pellet | 2 | 2.1% |
| Solution | 2 | 2.1% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Dipeptidyl Peptidase 4 Inhibitor | 10 |
| Biguanide | 9 |
| Cytomegalovirus DNA Terminase Complex Inhibitor | 6 |
| Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor | 5 |
| Inactivated Hepatitis B Virus Vaccine | 5 |
| Substance P/Neurokinin-1 Receptor Antagonist | 5 |
| Orexin Receptor Antagonist | 4 |
| Inactivated Human Papillomavirus Vaccine | 4 |
| Inactivated Pneumococcal Vaccine | 4 |
| Inactivated Hepatitis A Virus Vaccine | 4 |
| Penem Antibacterial | 3 |
| Programmed Death Receptor-1 Blocking Antibody | 3 |
| Soluble Guanylate Cyclase Stimulator | 3 |
| Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor | 3 |
| Renal Dehydropeptidase Inhibitor | 2 |
| Endoglycosidase | 2 |
| Live Attenuated Measles Virus Vaccine | 2 |
| Live Attenuated Mumps Virus Vaccine | 2 |
| Live Attenuated Rubella Virus Vaccine | 2 |
| Echinocandin Antifungal | 2 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Lipfendra | 0006-5084 | Tablet, film coated | New drug applications (NDA) | July 15, 2026 |
| RotaTeq | 0006-4379 | Solution | Biologics (BLA) | May 15, 2026 |
| Idvynso | 0006-5092 | Tablet, film coated | New drug applications (NDA) | April 23, 2026 |
| Keytruda qlex | 0006-5083 | Injection, solution | Biologics (BLA) | September 19, 2025 |
| Keytruda qlex | 0006-3083 | Injection, solution | Biologics (BLA) | September 19, 2025 |
| Enflonsia | 0006-5073 | Injection, solution | Biologics (BLA) | June 9, 2025 |
| Prevymis | 0006-5086 | Pellet | New drug applications (NDA) | August 30, 2024 |
| Prevymis | 0006-5085 | Pellet | New drug applications (NDA) | August 30, 2024 |
| Capvaxive | 0006-4347 | Injection, solution | Biologics (BLA) | June 17, 2024 |
| Winrevair | 0006-5091 | Kit | Biologics (BLA) | March 26, 2024 |
| Winrevair | 0006-5090 | Kit | Biologics (BLA) | March 26, 2024 |
| Winrevair | 0006-5088 | Kit | Biologics (BLA) | March 26, 2024 |
| Winrevair | 0006-5087 | Kit | Biologics (BLA) | March 26, 2024 |
| Sterile diluent | 0006-4175 | Injection | Biologics (BLA) | August 21, 2023 |
| Welireg | 0006-5331 | Tablet, film coated | New drug applications (NDA) | August 13, 2021 |
| Vaxneuvance | 0006-4329 | Injection, suspension | Biologics (BLA) | July 16, 2021 |
| Verquvo | 0006-5030 | Tablet, film coated | New drug applications (NDA) | February 1, 2021 |
| Verquvo | 0006-5029 | Tablet, film coated | New drug applications (NDA) | February 1, 2021 |
| Verquvo | 0006-5028 | Tablet, film coated | New drug applications (NDA) | February 1, 2021 |
| Recarbrio | 0006-3856 | Injection, powder, for solution | New drug applications (NDA) | January 6, 2020 |
| Imipenem anhydrous, cilastatin, and relebactam anhydrous | 0006-0138 | Injection, powder, for solution | Drugs for further processing | January 6, 2020 |
| Ervebo | 0006-4293 | Injection, solution | Biologics (BLA) | December 19, 2019 |
| Delstrigo | 0006-5007 | Tablet, film coated | New drug applications (NDA) | July 20, 2018 |
| Pifeltro | 0006-3069 | Tablet, film coated | New drug applications (NDA) | July 20, 2018 |
| Segluromet | 0006-5374 | Tablet, film coated | New drug applications (NDA) | December 19, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.